{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:35:27Z","timestamp":1791477327580,"version":"4.3.4"},"reference-count":38,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2010,7,9]],"date-time":"2010-07-09T00:00:00Z","timestamp":1278633600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Exp Pharma Physio"],"published-print":{"date-parts":[[2010,10]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>1. The interplay between the immune and renin\u2013angiotensin systems is emerging as a crucial factor in the development and progression of hypertension. The aim of the present study was to determine the involvement of immune cells in the hypertension and renal injury produced by a non\u2010angiotensin II\u2010dependent form of hypertension, namely deoxycorticosterone acetate (DOCA)\u2010salt\u2010induced hypertension, in rats.<\/jats:p><jats:p>2. Male Sprague\u2010Dawley rats underwent uninephrectomy and received either a sustained\u2010release pellet of DOCA s.c. and 0.9% NaCl (saline) to drink for 21\u2003days or a placebo pellet and water to drink for 21\u2003days. Additional groups of DOCA\u2010salt\u2010 and placebo\u2010treated rats were treated concurrently with the immune suppressant mycophenolate mofetil (MMF; 30\u2003mg\/kg per day). Rats were placed in metabolic cages for 24\u2003h urine collection prior to and at weekly intervals during the 21\u2003day experimental period.<\/jats:p><jats:p>3. Mycophenolate mofetil significantly attenuated the development of hypertension in DOCA\u2010salt rats compared with untreated DOCA\u2010salt hypertensive rats (mean arterial pressure by telemetry on Day 18 146\u2003\u00b1\u20037 vs 180\u2003\u00b1\u20033\u2003mmHg, respectively; <jats:italic>P<\/jats:italic>\u2003&lt;\u20030.001), as well as proteinuria (87\u2003\u00b1\u200327 vs 305\u2003\u00b1\u200363\u2003mg\/day, respectively, on Day 21) and albuminuria (51\u2003\u00b1\u200315 vs 247\u2003\u00b1 73\u2003mg\/day, respectively, on Day 21). Creatinine clearance was better preserved in MMF\u2010treated DOCA\u2010salt rats compared with untreated DOCA\u2010salt rats (0.74\u2003\u00b1\u20030.07 vs 0.49\u2003\u00b1\u20030.09\u2003mL\/min, respectively; <jats:italic>P<\/jats:italic>\u2003&lt;\u20030.05), but was still significantly reduced compared with that in the placebo group (1.15\u2003\u00b1\u20030.12\u2003mL\/min; <jats:italic>P<\/jats:italic>\u2003&lt;\u20030.05). Finally, MMF treatment significantly attenuated the DOCA\u2010salt\u2010induced rise in renal cortical T\u2010lymphocyte and macrophage infiltration (<jats:italic>P\u2003<\/jats:italic>&lt;\u20030.05).<\/jats:p><jats:p>4. These data indicate that immune cells play a deleterious role in both the hypertension and renal injury associated with DOCA\u2010salt hypertension.<\/jats:p>","DOI":"10.1111\/j.1440-1681.2010.05428.x","type":"journal-article","created":{"date-parts":[[2010,7,12]],"date-time":"2010-07-12T05:31:57Z","timestamp":1278912717000},"page":"1016-1022","source":"Crossref","is-referenced-by-count":41,"title":["Immunosuppression with mycophenolate mofetil attenuates the development of hypertension and albuminuria in deoxycorticosterone acetate\u2010salt hypertensive rats"],"prefix":"10.1111","volume":"37","author":[{"given":"Erika I","family":"Boesen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas L","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer S","family":"Pollock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M","family":"Pollock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,7,9]]},"reference":[{"key":"e_1_2_6_2_2","first-page":"523","article-title":"Evidence for an initial, thymus independent and a chronic, thymus dependent phase of DOCA and salt hypertension in mice","volume":"84","author":"Svendsen UG","year":"1976","journal-title":"Acta Pathol. Microbiol. Scand. A"},{"key":"e_1_2_6_3_2","first-page":"321","article-title":"Antihypertensive effect of neonatal thymectomy in the genetically hypertensive LH rat","volume":"8","author":"Bataillard A","year":"1986","journal-title":"Thymus"},{"key":"e_1_2_6_4_2","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1097\/00004872-199512010-00012","article-title":"Silica attenuates hypertension in Lyon hypertensive rats","volume":"13","author":"Bataillard A","year":"1995","journal-title":"J. Hypertens."},{"key":"e_1_2_6_5_2","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1097\/00004872-199512010-00014","article-title":"Partial transfer of genetic hypertension by lymphoid cells in Lyon rats","volume":"13","author":"Renaudin C","year":"1995","journal-title":"J. Hypertens."},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20070657"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.aids.0000171410.76607.f8"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.0197.2001"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00199.2002"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2005.00508.x"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2005.00674.x"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.0000228320.23697.29"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.00487.2006"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00527.2007"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpregu.00821.2007"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2006080918"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.0000198545.01860.90"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.00708.2005"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpregu.90521.2008"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(72)90050-2"},{"key":"e_1_2_6_21_2","volume-title":"Guide for the Care and Use of Laboratory Animals","author":"Institute of Laboratory Animal Research, Commission on Life Sciences, National Research Council","year":"1996"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.2001.281.1.F144"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.V1281630"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpregu.1998.275.1.R245"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpregu.00645.2006"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(03)00054-8"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.0000025146.19104.FE"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2008.10.002"},{"key":"e_1_2_6_29_2","first-page":"479","article-title":"Parallel determination of mineralocorticoid and glucocorticoid receptors in T\u2010 and B\u2010lymphocytes of human spleen","volume":"118","author":"Armanini D","year":"1988","journal-title":"Acta Endocrinol."},{"key":"e_1_2_6_30_2","first-page":"S157","article-title":"Binding of agonists and antagonists to mineralocorticoid receptors in human peripheral mononuclear leucocytes","volume":"3","author":"Armanini D","year":"1985","journal-title":"J. Hypertens. Suppl."},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.109.131110"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0802886"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1254\/jphs.FP0060801"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000127949.05756.9D"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpregu.00298.2009"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004872-199501000-00017"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.tp.0000186390.10150.66"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.01118.2006"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm.1960"}],"container-title":["Clinical and Experimental Pharmacology and Physiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1440-1681.2010.05428.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1440-1681.2010.05428.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T18:19:17Z","timestamp":1697393957000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1440-1681.2010.05428.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7,9]]},"references-count":38,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["10.1111\/j.1440-1681.2010.05428.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1440-1681.2010.05428.x","archive":["Portico"],"relation":{},"ISSN":["0305-1870","1440-1681"],"issn-type":[{"value":"0305-1870","type":"print"},{"value":"1440-1681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,7,9]]}}}